<?xml version="1.0" encoding="UTF-8"?>
<p>This open-label, randomized clinical trial was conducted to assess the efficacy and safety of IFN-β-1a in the treatment of adult (aged ≥18 years) patients diagnosed with COVID-19. Patients were admitted from 29 February to 3 April 2020 in Imam Khomeini Hospital Complex, the main central hospital in Tehran, capital of Iran.</p>
